AstraZeneca’s next-gen ERT fails a Phase 3 Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 1 April, 2026

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

SPOTLIGHT Watch Post-Hoc Live: MAHA, vaccine politics and the risk for Republicans — with former Congressman Michael Burgess

news Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts FDA identifies eight deaths tied to Amgen’s rare disease drug Tavneos AstraZeneca's next-gen hopeful for a rare bone condition fails pivotal trial

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

John Carroll’s R&D 15 report is back — and this year, he’s bringing some of the industry’s top research chiefs into the conversation to break down what the data means, what’s shifting, and where biopharma R&D is headed. Join us to find out what comes next.

ENDPOINTS PHARMA Pharma goes on $25.5B, eight-day acquisition spree •  Updated: Biogen highlights kidney disease ambitions in $5.6B Apellis buyout •  Eli Lilly to buy Centessa for $6.3B to get sleep disorder drug Exclusive: ViiV R&D head Kimberly Smith heads to retirement after three decades in HIV care Novo Nordisk launches subscription program for Wegovy drugs

Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera

in case you missed it 1. Exclusive: First clinical trial of tRNA therapy, a new disease-agnostic form of genetic medicine, will start soon 2. Exclusive: In promising early readout, Enveda shows Dupixent-rivaling potential in atopic dermatitis 3. Astellas doesn’t pick up AviadoBio’s gene therapy, but nonprofit funding will move it forward 4. Merck joins forces with small startup to find therapeutic antibodies 5. Colorado biotech Ambrosia lands $100M for oral GLP-1